金河生物(002688.SZ):豬圓環病毒2型、豬肺炎支原體二聯滅活疫苗獲得進口獸藥註冊證書
格隆匯11月15日丨金河生物(002688.SZ)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》規定,公司控股子公司美國法瑪威於近日獲得農業農村部核發的《進口獸藥註冊證書》,具體情況如下:
進口獸藥名稱:豬圓環病毒2型、豬肺炎支原體二聯滅活疫苗(重組桿狀病毒P株+P株);作用與用途:用於預防豬圓環病毒2型感染引起的疾病和預防豬支原體肺炎。
豬圓環病毒病是由圓環病毒引起的斷奶仔豬多系統衰竭綜合徵(PMWS)、豬皮炎腎病綜合徵(PDNS)等多種病症的統稱,嚴重危害養豬業生產;豬支原體肺炎是最常發生、流行最廣最難淨化的重要疫病之一。豬圓環病毒、豬肺炎支原體常常混合感染,對養豬業造成重大經濟損失。
豬圓環病毒2型、豬肺炎支原體二聯滅活疫苗(重組桿狀病毒P株+P株)(以下簡稱“圓支二聯苗”)是美國法瑪威公司在繼承原有產品喘泰克(豬支原體肺炎滅活疫苗(P)株和豬支原體肺炎複合佐劑滅活疫苗(P)株)優秀品質的基礎上精心開發的聯苗產品,其品質也與金河佑本至純至美的理念一脈相承。與針對兩種疾病的單苗相比,圓喘泰克協同增強了各自抗原組分的免疫性能,達到了“1+1>2”的免疫效果。
此次獲得的進口獸藥註冊證書將對豐富公司動物疫苗產品品種,提升產品品質和市場競爭力產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.